共查询到19条相似文献,搜索用时 68 毫秒
1.
目的:探讨超声造影定量分析肝动静脉渡越时间对结直肠癌肝转移的预测价值。方法:研究对象包括58例明确诊断为结直肠癌肝转移的患者(转移组),48例具有结直肠癌史同时无肝内转移的患者(待查组)及39例健康志愿者(对照组)。所有研究对象均行超声造影检查,分析肝动脉及肝静脉到达时间并计算其差值记为肝动静脉渡越时间(HAVTT)。待查组患者在3-6个月后行超声造影检查及增强CT/MRI检查来判断是否发生肝内转移。结果:转移组HAVTT较正常组明显缩短(6.58SVs10.75s,P=0.0000)。以HAVTT小于8秒为标准诊断结直肠癌肝转移,准确性、敏感性及特异性分别为97.93%、96.55%及100%。以HAVTT小于8秒为标准预测结直肠癌肝转移,准确性、敏感性及特异性分别为93.75%、66.67%及95.56%。结论:HAVTT可用来预测结直肠癌肝转移。HAVTT缩短者需进一步检查或密切随访。 相似文献
2.
目的:探讨宴时超声造影在肝肿瘤诊断中的应用价值。方法:经静脉注射造影剂Sono Vue后,对45(男24、女21)例肝肿瘤患者(共63个病灶),在低机械指数状态下进行实时超声造影检查,并对录像资料进行回放、分析诊断,与基础超声诊断结果进行比较,通过病理证实。结果:基础超声、实时超声造影对肝肿瘤病灶的检出率分别为87.3%和96.8%,最大径小于1.0cm的肿瘤,基础超声、实时超声造影对肝肿瘤病灶的检出率分别是41.7%和83.3%。基础超声有52.4%(33/63)的肿瘤边界显示不清晰,实时超声造影有6.3%(4/63)的肿瘤边界显示不清。对肝恶性肿瘤的诊断,基础超声诊断的敏感性、特异性、住确性分别是51.4%、66.7%和56.4%;实时超声造影诊断的敏感性、特异性、准确性分别为95.3%,94.4%和95.1%,两者之间差异具有统计学意义(P〈0.05)。结论:实时超声造影在发现肿瘤数目、大小、边界较基础超声提供的信息多,实时超声造影对肝肿瘤性质鉴别优于基础超声。 相似文献
3.
目的:探讨超声造影(CEUS)在肝硬化合并肝内局灶性小病灶(≤3.0 cm)中的诊断价值。方法:选择我院自2010年4月至2014年8月患有肝硬化合并肝内局灶性小病灶的患者100例,采用MRI、CT及病理确定病灶良恶性,同时对比影像结果,计算常规超声和CEUS的准确性。结果:MRI、CT及病理确定病灶105个,其中恶性组45例,良性组60例,超声造影技术能清晰的显示出血流灌注的情况以及动脉相、门脉相及延迟相的特点。数据统计结果显示常规超声和CEUS的准确性、特异性和敏感性分别为59.05%、77.78%、45.00%和95.24%、95.56%、95.00%,两者之间的差异具有统计学意义(P0.05)。结论:相对于常规超声,CEUS对患有肝硬化合并肝内局灶性小病灶的患者具有更高的诊断价值。 相似文献
4.
肝脏是人体最大的腺体.肝脏占位性病变是临床上常见的一类肝脏疾病,这些病变的病理类型复杂,临床上诊断往往十分困难.传统超声在诊断肝脏占位性病变上取得了不小的成绩,但仍有不少局限.超声造影的出现为诊断肝脏占位性病变提供了许多有价值的信息.随着超声造影剂及其成像技术的迅速发展,超声造影技术的临床应用日趋成熟,使肝占位性病变的诊断的准确性及敏感度都有了不小的提高,本文就新型超声造影剂的发展应用在肝占位性病变及肿瘤介入治疗评价中的价值进行综述. 相似文献
5.
目的:探讨超声造影与超声弹性成像鉴别诊断甲状腺良恶性结节的临床价值。方法:回顾性分析2011年1月-2013年6月我院经病理证实的128例甲状腺占位性病变患者(160个结节)的超声影像学资料,其中恶性结节68个,良性占位92个,评估实时超声造影与超声弹性成像诊断甲状腺良性与恶性结节的敏感性、特异性、准确率、阳性预测值及阴性预测值。结果:甲状腺良性结节超声造影检查以快进慢出、高增强为主;恶性结节以慢进快出、低增强为主。超声造影诊断甲状腺良、恶性结节的灵敏度、特异度与阳性预测值、阴性预测值及其诊断符合率分别为91.18%、92.39%、91.18%、93.41%、91.88%;超声弹性成像分别为89.71%、90.22%、87.14%、92.22%、90.00%,联合检查分别为94.12%、95.65%、94.12%、95.65%、95.00%,均高于常规超声的57.35%、72.83%、60.94%、69.79%、65.63%,比较差异有统计学意义(P0.05);联合检查灵敏度、符合率明显高于超声造影与超声弹性成像单一检查,比较差异有统计学意义(P0.05)。结论:超声造影与超声弹性成像在鉴别诊断甲状腺良恶性结节中均具有较高的应用价值,两种方法联合检查灵敏度及准确性更高。 相似文献
6.
目的:探讨常规超声及超声造影在肝癌中的诊断及鉴别诊断价值。方法:收集2009年5月至2013年10月在我院进行住院诊治的肝癌患者120例,选择飞利浦IU22进行常规超声检查,选择飞利浦的IU22进行超声造影检查。结果:常规超声检查68例为低回声,20例为强回声,12例为等回声,17例为混合性回声,3例误诊为肝外病变,检出率为97.5%。肝癌组织的AT、TTP、ACT值明显晚于正常肝组织(P0.05),而BI、PI、MTT与BF值对比差异无明显差异(P0.05)。Spearman相关分析显示超声造影灌注参数AT、TTP、ACT与肿瘤分化程度呈正向相关性(P0.05)。结论:常规超声及超声造影在肝癌中的诊断及鉴别都有很好的应用价值,超声造影的应用可反映正常和病变组织的血流灌注情况,从而提高肝癌诊断的准确性。 相似文献
7.
摘要 目的:探讨高频超声与超声造影对甲状腺癌侵袭性的诊断价值。方法:2016年2月至2019年10月选择在本院诊治的甲状腺癌患者88例作为研究对象,所有患者都给予高频超声与超声造影诊断,记录影像学特征。检测所有患者侵袭性指标表达情况并判断诊断价值。结果:在88例患者中,病理检出颈部转移性淋巴结22例(转移组),检出率为25.0 %。转移组的病灶钙化、边界模糊、纵横比≥1、内部血流信号、低回声等比例都显著高于非转移组(P<0.05)。转移组的淋巴结长径、短径显长于非转移组(P<0.05),两组长短径比值对比无差异(P>0.05)。转移组的峰值强度(Peak intensity,PI)、平均通过时间(Mean transit time,MTT)、达峰时间(Peak time,TIP)值显著高于非转移组(P<0.05)。转移组的ADAM9、Notch-1、CXCR4 mRNA相对表达水平都显著高于非转移组(P<0.05)。高频超声与超声造影对甲状腺癌侵袭性的诊断敏感性为95.2 %和95.5 %,特异性为100.0 %和100.0 %。结论:高频超声与超声造影对甲状腺癌侵袭性都有很好的诊断敏感性与特异性,可为甲状腺癌颈部淋巴结转移的诊断提供补充性的定性和定量分析的方法。 相似文献
8.
目的:比较超声造影参数与多普勒参数评估门静脉高压(PHT)的准确性,旨在探讨超声造影用于PHT诊断的可行性。方法:选择我院收治的肝硬化合并PHT患者50例,定义为PHT组,所有患者均自愿接受FPP的测定。另选择未合并PHT的乙肝患者50例,定义为对照组。所有患者测量门静脉内径(PVD),门静脉流速(PVV),肝动脉阻力指数(HARI)和脉搏指数(HAPI)。再计算出肝动脉到门静脉的渡越时间(PV-HA)和肝动脉到肝静脉的渡越时间(HV-HA)。结果:PHT组的PVD、HARI和HAPI均显著大于对照组,差异存在统计学意义(PVD:t=3.421,P=0.002;HARI:t=3.223,P=0.001;HAPI:t=3.108,P=0.000)。另外,PHT组的HV-HA显著小于对照组,差异有统计学意义(t=4.868,P=0.000)。而PHT组的PV-HA则显著大于对照组,差异有统计学意义(t=3.969,P=0.000)。HV-HA与FPP呈负相关(r=-0.878,P=0.000),PV-HA与FPP呈正相关(r=0.829,P=0.000),HARI和HAPI虽然同样与FPP呈正相关,但相关性较造影参数低(HARI:r=0.658,P=0.000;HAPI:r=0.742,P=0.000)。结论:多普勒参数与FPP的相关性较低。超声造影参数HV-HA和PV-HA能够敏感提示门静脉高压并且与FPP的相关性更高,所以能更准确、可靠地评估门静脉压力。 相似文献
9.
10.
目的:分析超声弹性成像与超声造影对肝肿瘤的诊断效果。方法:收集我院2015年3月至2016年3月收治的肝肿瘤患者76例,术前均行超声弹性成像和超声造影检查,比较超声弹性成像和超声造影与病理诊断(黄金标准)的结果。结果:超声弹性成像与病理检查结果比较无统计学差异(P0.05);超声造影与病理检查结果无统计学差异(P0.05);超声弹性成像和超声造影的敏感性、特异性、准确性无统计学差异(P0.05)。结论:超声弹性成像、超声造影对肝肿瘤诊断中均有重要价值,建议二者联合检测,提高肝肿瘤检出准确率。 相似文献
11.
目的:评估超声造影(CEUS)gl导下微波消融(MwA)治疗肝癌的有效性及应用价值。方法:108例肝癌患者,共147个病灶经MWA治疗。根据患者在做常规超声检查时,是否有扫查不清晰的结节或其他影像学检查提示可能存在多发结节等,分成CEUS族和对照组。CEUS组41名患者,年龄(57.9±7.8)岁,共57个病灶,平均直径(2.4±1.5)cm,经超声造影引导下行微波消融治疗。对照组67名患者,年龄(55.5±8.9)岁,共90个病灶,平均直径(2.6±1.7)cm,常规超声引导下同种条件行微波消融治疗。治疗后对两组患者进行6~12个月随访。结果:CEUS组的57个病灶均清晰显示其位置、数目、大小、边界、形态,完全消融的结节为55个,未完全消融的结节为2个。对照组67名患者的90个病灶,完全消融的病灶78个;未完全消融的结节12个。CEUS组完全消融率高于病例对照组(96.49%VS86.67%;P〈0.05)。随访6~12个月后发现,CEUS组完全消融率高于病例对照组(P〈0.05),差异有统计学意义。结论:CEUS能更好的显示病灶的位置、数目、大小,更精确显示病灶边界、范围,造影引导下MWA是一种有效提高完全消融效率的方法,具有较大应用价值。 相似文献
12.
目的:利用超声造影研究高分化和低分化肝癌患者的肿瘤血流灌注情况,探讨超声造影在肝癌分级的诊断价值。方法:选择我院原发性肝癌(HCC)患者65例并根据活检肝细胞癌病变和肿瘤分级不同分为A组37例(高分化组)和B组28例(低分化组),对两组患者行超声造影检查,分析超声造影的血流灌注状态。结果:A组与B组病灶的到达时间(AT)、峰值时间(TTP)和峰值强度(PI)均存在显著的差异性(tAT=7.266,PAT=0.000;tTTP=5.966,PTTP=0.000;tPI=8.219,PPI=0.000)。A组与B组间的病灶增强时间(1)、增强斜率(2)、清除时间(3)、清除斜率(4)具有差异,并且差异具有统计学意义(t1=7.266,PI=0.000;t2=317,P2=0.000;t3=8.880,P3=0.000;t4=6.178,P4=0.000)。结论:超声造影可作为一种新型的肝癌分级方法,对于早期诊断肝癌和获得肿瘤分级具有很大的临床价值。 相似文献
13.
目的:探讨计算机断层扫描血管造影(CTA)联合对比增强超声(CEUS)在锁骨上皮瓣术前设计中的应用价值.方法:将2016年1月~2018年12月本院收治的15例锁骨上皮瓣术前患者作为研究对象.所有患者术前进行CTA和CEUS联合检查以观察锁骨上动脉穿支解剖变异及走行,应用于锁骨上皮瓣术前的辅助设计,评估该方法的成功率和... 相似文献
14.
Objectives
To evaluate MRI findings in patients with primary biliary cirrhosis (PBC) and to determine the value of MRI in the diagnosis of PBC and assessment of liver fibrosis.Materials and Methods
This study reviewed the prevalence of MRI abnormalities seen in 45 PBC patients in the past four years, including 33 patients who underwent liver biopsy. Correlation between the MRI findings and the pathological stage was determined.Results
There were 33 patients who underwent liver biopsy. Twenty-five patients (75.8%) had non-homogeneous changes in the liver signal intensity, 25 (75.8%) had a periportal halo sign, and 29 (87.9%) had lymphadenopathy. The short axis of the enlarged lymph nodes was a mean of 1.2±0.3 cm. A strong positive correlation was observed between histological stage and the inhomogeneity of liver signal intensity (P<0.001). There were significant differences among the four histological stages based on the periportal halo sign (P=0.034), and the grading of the periportal halo sign was found to be significantly correlated with the histological stage (P<0.001). Grading of the periportal halo sign was significantly different at stage II versus III, and stage III versus IV; no significant difference was found between stages I and II. There were also no significant differences among the four histological states in the occurrence and size of enlarged lymph nodes (P=0.674 and P=0.394).Conclusion
MRI is valuable in the diagnosis of PBC, and the periportal halo sign and liver signal intensity help to evaluate the degree of liver fibrosis. 相似文献15.
目的:探讨彩色高频超声多普勒在男性乳腺增生症中的应用价值.方法:收集我院2010年8月至2012年9月门诊及住院疑似男性乳腺增生症患者63例,应用彩色高频超声对63例(77只)男性乳腺增生症患者检查,分析其声像图特点并采用自身前后对照的方法与临床走访或病理诊断相比较.结果:超声诊断男性乳腺增生60例(74只),疑为男性乳腺癌2例,疑为增生伴炎性改变1例.临床或病理证实男性乳腺增生63例(77只).彩色高频超声多普勒在诊断男性乳腺增生上与临床金标准相比,符合率为96.1%.结论:彩色高频超声诊断男性乳腺增生症是一种准确、无创、简便的方法,有较高的应用价值. 相似文献
16.
Tomohiro Sekiguchi Takeji Umemura Naoyuki Fujimori Soichiro Shibata Yuki Ichikawa Takefumi Kimura Satoru Joshita Michiharu Komatsu Akihiro Matsumoto Eiji Tanaka Masao Ota 《PloS one》2015,10(6)
The development of simple, noninvasive markers of liver fibrosis is urgently needed for primary biliary cirrhosis (PBC). This study examined the ability of several serum biomarkers of cell death to estimate fibrosis and prognosis in PBC. A cohort of 130 patients with biopsy-proven PBC and 90 healthy subjects were enrolled. We assessed the utility of the M30 ELISA, which detects caspase-cleaved cytokeratin-18 (CK-18) fragments and is representative of apoptotic cell death, as well as the M65 and newly developed M65 Epideath (M65ED) ELISAs, which detect total CK-18 as indicators of overall cell death, in predicting clinically relevant fibrosis stage. All 3 cell death biomarkers were significantly higher in patients with PBC than in healthy controls and were significantly correlated with fibrosis stage. The areas under the receiver operating characteristic curve for the M65 and M65ED assays for differentiation among significant fibrosis, severe fibrosis, and cirrhosis were 0.66 and 0.76, 0.66 and 0.73, and 0.74 and 0.82, respectively. In multivariate analysis, high M65ED (hazard ratio 6.13; 95% confidence interval 1.18–31.69; P = 0.031) and severe fibrosis (hazard ratio 7.45; 95% confidence interval 1.82–30.51; P = 0.005) were independently associated with liver-related death, transplantation, or decompensation. High serum M65ED was also significantly associated with poor outcome in PBC (log-rank test; P = 0.001). Noninvasive cell death biomarkers appear to be clinically useful in predicting fibrosis in PBC. Moreover, the M65ED assay may represent a new surrogate marker of adverse disease outcome. 相似文献
17.
目的:分析子宫不同占位性病变的声像学特点和和误诊原因,探讨超声诊断价值.方法:回顾性分析我院185例不同占位性病变经腹部超声图像资料,观察病变形态、大小、病变位置、包膜、边缘及后方回音等.结果:185例患者中,经体表超声检测出139例不同占位性病变患者,符合率为75.14%;误诊46例,误诊率为24.86%,误诊原因与病变形态、内部回音、宫腔线所表现出的相似性有关.结论:腹部超声能够较准确地诊断出子宫不同占位性病变,结合患者病史和临床症状,可以实现其更好的利用价值. 相似文献
18.
Peter G. Traber Hsin Chou Eliezer Zomer Feng Hong Anatole Klyosov Maria-Isabel Fiel Scott L. Friedman 《PloS one》2013,8(10)
Galectin-3 protein is critical to the development of liver fibrosis because galectin-3 null mice have attenuated fibrosis after liver injury. Therefore, we examined the ability of novel complex carbohydrate galectin inhibitors to treat toxin-induced fibrosis and cirrhosis. Fibrosis was induced in rats by intraperitoneal injections with thioacetamide (TAA) and groups were treated with vehicle, GR-MD-02 (galactoarabino-rhamnogalaturonan) or GM-CT-01 (galactomannan). In initial experiments, 4 weeks of treatment with GR-MD-02 following completion of 8 weeks of TAA significantly reduced collagen content by almost 50% based on Sirius red staining. Rats were then exposed to more intense and longer TAA treatment, which included either GR-MD-02 or GM-CT-01 during weeks 8 through 11. TAA rats treated with vehicle developed extensive fibrosis and pathological stage 6 Ishak fibrosis, or cirrhosis. Treatment with either GR-MD-02 (90 mg/kg ip) or GM-CT-01 (180 mg/kg ip) given once weekly during weeks 8–11 led to marked reduction in fibrosis with reduction in portal and septal galectin-3 positive macrophages and reduction in portal pressure. Vehicle-treated animals had cirrhosis whereas in the treated animals the fibrosis stage was significantly reduced, with evidence of resolved or resolving cirrhosis and reduced portal inflammation and ballooning. In this model of toxin-induced liver fibrosis, treatment with two galectin protein inhibitors with different chemical compositions significantly reduced fibrosis, reversed cirrhosis, reduced galectin-3 expressing portal and septal macrophages, and reduced portal pressure. These findings suggest a potential role of these drugs in human liver fibrosis and cirrhosis. 相似文献

